Breaking news on immune system
GenVec Announces Grant For RSV Vaccine Program published
Fri, 09 May 2008 03:00:00 PDT
GenVec, Inc. (Nasdaq:GNVC) announced that it has received an Advanced Technology Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases, of the National Institutes of Health, to support the Company's efforts to develop vaccines for the prevention of respiratory syncytial virus (RSV). The SBIR grant, valued at $600,000 over two years, will support work being conducted exclusively at GenVec.
Immunization Levels Among Inner City Children Enrolled In Subsidized Childcare Just Over Half Of National Averages, USA published
Fri, 09 May 2008 03:00:00 PDT
The Centers for Disease Control and Prevention (CDC) conduct the National Immunization Survey to track rates of recommended immunization around the country. Since 2006, up-to-date (UTD) immunization of 2 year olds has held steady at about 82% of children nationally. Even of 19-35 month olds living in households below the federal poverty level, 92% are UTD with the basic set of vaccinations, according to CDC data.
Flu Vaccine Less Effective In Winter 2007/2008 Than In Previous Winters published
Wed, 07 May 2008 01:00:00 PDT
A new Harris Poll confirms the findings of a recent report by the Centers for Disease Control and Prevention (CDC) that the vaccine used to prevent the flu this last winter was less effective than the flu vaccines used in previous winters. In three previous winters people receiving flu vaccines were 33 percent, 43 percent and 24 percent less likely to get the flu than people who did not get flu shots.
Novartis Menveo(R) Vaccine Shows Strong Immune Response Against Four Types Of Meningitis Disease In Pivotal Phase III Study published
Wed, 07 May 2008 01:00:00 PDT
A vaccine being developed by Novartis against four types of meningitis produces a better antibody response than a commonly used existing vaccine, data released today shows.
New Discovery On Role Of Vital Protein That Fights Meningitis published
Wed, 07 May 2008 01:00:00 PDT
University of Leicester research assigns hitherto unappreciated importance to protein of the body's immune defence system A University of Leicester researcher has discovered how a protein in the blood - linked to defence against meningitis - plays a more vital role than previously understood in the body's immune defence system. The published research has helped to advance medical understanding of how the body defends against disease and heals itself.
Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate And Technology published
Tue, 06 May 2008 02:00:00 PDT
Emergent BioSolutions Inc. (NYSE: EBS) announced that it has completed the acquisition of all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology from VaxGen, Inc. Recent improvements to the rPA vaccine, specifically related to stability, suggests that it is well positioned to be a leading candidate for an award under a request for proposal (RFP) recently issued by the U.S. Department of Health and Human Services (HHS).
Annual Conference On Vaccine Research To Highlight Not Only Health Benefits But Also Economic Gains published
Tue, 06 May 2008 00:00:00 PDT
Vaccines don't just keep children healthy, they also lead to more productive adult workers who can earn higher wages and save more money, according to Dr. David E. Bloom, a labor economist at the Harvard School of Public Health. Bloom, who has studied the economic impact of vaccination in developing countries, will be the keynote speaker at the 11th Annual Conference on Vaccine Research sponsored by the National Foundation for Infectious Diseases (NFID).
Starting Flu Vaccination In August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors' Visits published
Tue, 06 May 2008 00:00:00 PDT
Research presented at the annual meeting of the Pediatric Academic Societies (PAS) shows that by starting flu vaccinations in August -- ahead of the start of the typical flu vaccination season -- healthcare providers could reach an additional 10.7 million children when these children are already in the doctor's office.
It's The Virus, Stupid: Immune Exhaustion In HIV Infection published
Tue, 06 May 2008 00:00:00 PDT
As HIV disease progresses in a person infected with the HIV virus, a group of cells in the immune system, the CD8+ T lymphocytes, become "exhausted," losing many of their abilities to kill other cells infected by the virus. For many years scientists have debated whether this exhaustion of CD8+ T cells is the cause, or the consequence, of persistence of the HIV virus.
3M Collaborates With Infectious Disease Research Institute On Vaccine Adjuvants published
Mon, 05 May 2008 00:00:00 PDT
3M Drug Delivery Systems announces the signing of a non-exclusive license agreement with the Infectious Disease Research Institute (IDRI) in support of vaccine research for humanitarian efforts in developing countries. Under the agreement, 3M will donate its patented toll-like receptor (TLR) immune response modifier compounds. 3M's patented TLR immune response modifier compounds, which may be useful as vaccine adjuvants, will be used by IDRI to research new vaccines.
Peanut Allergy Immunotherapy Should Be Available In Five Years published
Sun, 04 May 2008 00:00:00 PDT
Some form of immunotherapy is expected to be available for peanut allergy within the next five years. But the reasons for the increasing prevalence of this allergic reaction remain unclear. The issues are discussed by Professor Wesley Burks, Duke University Medical Center, NC, USA, in a Seminar in this week's edition of The Lancet.
Malaria Vaccine Pioneer, Ruth Nussenzweig, Awarded The Albert B. Sabin Gold Medal In Vaccinology published
Sat, 03 May 2008 00:00:00 PDT
Continuing its 15-year tradition of recognizing extraordinary accomplishments and groundbreaking research in the field of vaccinology, Sabin Vaccine Institute (SVI) has announced Dr. Ruth S. Nussenzweig as the recipient of the 2008 Albert B. Sabin Gold Medal for her outstanding malaria-focused initiatives. SVI has also named Dr.
ALAS Foundation's Wyclef Jean Joins PAHO To Boost Child Vaccination In Haiti published
Fri, 02 May 2008 13:00:00 PDT
Haiti's largest vaccination effort in history-aimed at more than 5 million children and youths-will be kicked off with a new public service announcement (PSA) featuring Haitian musician, producer and writer Wyclef Jean, a founding member of the ALAS Foundation. The PSA, produced by the Pan American Health Organization (PAHO) in association with ALAS, is aimed at boosting participation in the upcoming campaign to vaccinate young Haitians against measles and rubella.
Journal Of Clinical Investigation Online Early Table Of Contents: May 1, 2008 published
Fri, 02 May 2008 04:00:00 PDT
Would tricyclic antidepressants help those with inflammatory bowel disease?It is thought that intestinal inflammatory conditions such as inflammatory bowel disease are exacerbated by depression. New data, generated by Stephen Collins and colleagues at McMaster University Medical Center, Canada, have characterized a mechanism by which experimental conditions that induced depressive-like behaviors in mice increased susceptibility to intestinal inflammation.
Measles Rise In US Is Imported, CDC published
Fri, 02 May 2008 03:00:00 PDT
The US Centers for Disease Control and Prevention (CDC) reported yesterday that the rise in measles cases so far this year is mostly imported, due to infected people coming into the US from other countries. For the seven years up to 2007, an average of 62 cases of measles a year have been reported to the CDC. But this year, up to 25th April, a total of 64 cases, 54 of which are imported from countries outside the US, have been reported.
Melbourn Offers Testing For New Era Of Nasal Inhalers - Laser Particle Sizing Ensures Accurate Delivery To Target published
Fri, 02 May 2008 01:00:00 PDT
Performance testing for nasal delivery devices is one of the new services being offered by Melbourn Scientific. Although traditionally used for the local administration of decongestants and anti-histamines, the potential of a nasal route is now being investigated for a wide range of treatments from the instant relief of panic attacks through to needle-free vaccinations. This creates new challenges for devices and requires new testing regimes.
Scientists Find Much Faster Way To Make Antibodies published
Thu, 01 May 2008 03:00:00 PDT
By pinpointing the window of opportunity when the human immune response to a particular pathogen peaks, scientists in the US have developed a much faster way to isolate the highly specific antibodies needed to make flu vaccines. The discovery may also lead to new and faster ways to produce vaccines and therapies to fight many other diseases.
British Veterinary Association Welcomes Arrival Of Bluetongue Vaccine published
Thu, 01 May 2008 01:00:00 PDT
The BVA has welcomed Defra Secretary of Sate Hilary Benn's announcement on the arrival of the first batch of Bovilis® BTv8 vaccine in the UK. Congratulating Intervet on the speed with which the vaccine had been developed BVA President Nick Blayney said "this news represents a crucial stage in our fight against Bluetongue.
KaloBios Completes Patient Dosing In Its U.S. Phase 1 Trial Of Its Third Drug Candidate, KB003 published
Wed, 30 Apr 2008 01:00:00 PDT
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced that the company has completed dosing subjects in a U.S. Phase 1 clinical trial of its third drug candidate, KB003. The study is a placebo-controlled, single-dose, dose-escalation Phase 1 trial in healthy volunteers, with safety and immunogenicity as primary endpoints.
CDC Says One Fourth Of Toddlers Behind On Vaccinations published
Wed, 30 Apr 2008 00:00:00 PDT
Your toddler might be improperly vaccinated, even if she's had every immunization the government recommends, according to a new study from the Centers for Disease Control and Prevention.More than one in four children are out of compliance with U.S. vaccination guidelines, say researchers led by Elizabeth Luman, Ph.D., of the National Center for Immunization and Respiratory Diseases.
Immune System Kick Started In Moist Nasal Lining In Sinusitis, Asthma And Colds published
Wed, 30 Apr 2008 00:00:00 PDT
Scientists at Johns Hopkins have outlined a new path for potential therapies to combat inflammation associated with sinusitis and asthma based on a new understanding of the body's earliest immune response in the nose and sinus cavities.
DOR BioPharma Initiates Non-Human Primate Efficacy Studies Of RiVaxTM, Its Vaccine Against Ricin Toxin published
Tue, 29 Apr 2008 14:00:00 PDT
DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or "The Company"), a late-stage biopharmaceutical company, announced the initiation of a comprehensive program to evaluate the efficacy of RiVax™ in non-human primates. RiVax™ is a recombinant subunit vaccine intended to protect humans against exposure to ricin toxin.
One-fifth Of US 2-year-olds Not Fully Immunized, Warns CDC published
Tue, 29 Apr 2008 08:00:00 PDT
The Centers for Disease Control and Prevention (CDC) warns that over 20% of American 2-year-olds are not fully immunized against infectious diseases to which they are particularly susceptible. A joint venture between the CDC and HHS (US Department of Health and Human Services) has been reminding parents, caregivers and healthcare providers of the benefits of immunization, as well as the importance of routine childhood vaccination. Dr.
New Front In Fight Against AIDS Virus published
Tue, 29 Apr 2008 03:00:00 PDT
A research group supported by the National Institutes of Health (NIH) has uncovered a new route for attacking the human immunodeficiency virus (HIV) that may offer a way to circumvent problems with drug resistance. In findings published in the online edition of the Proceedings of the National Academy of Sciences, the researchers report that they have blocked HIV infection in the test tube by inactivating a human protein expressed in key immune cells.
IFPMA Vaccine Task Force Funds University Of Cambridge Virus Mapmaker To Help WHO Global Influenza Surveillance Network published
Tue, 29 Apr 2008 02:00:00 PDT
The IFPMA Influenza Vaccine Supply international task force (IFPMA IVS) will grant EUR 200,000 to the Pathogen Evolution Group1 at the University of Cambridge in the UK, to support computerized mapping of the H1N1 and B influenza viruses. The group, recently described as "mapmaker for the world of influenza"2, has already mapped the H3N2 influenza virus.
)
|
|
